Effects of 5-HT3 receptor-selective agents on locomotor activity in rats following injection into the nucleus accumbens and the ventral tegmental area

European Journal of Pharmacology

Volumn 303, Issue 1-2, 1996, Pages 1-12

  Gillies, Donna M ^a   Mylecharane, Ewan J ^a   Jackson, David M ^b  

^a University of Sydney   (Australia)

^b Astra Arcus AB   (Sweden)

Author keywords

5 HT3 receptor; Dopaminergic modulations; Locomotor activity; Mesolimbic system, rat; Nucleus accumbens; Ventral tegmental area

Indexed keywords

2 METHYLSEROTONIN; 5 CARBAMOYLTRYPTAMINE; ALPHA METHYLSEROTONIN; DEXAMPHETAMINE; GRANISETRON; METIROSINE; METITEPINE; ONDANSETRON; RACLOPRIDE; RENZAPRIDE; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; 2 METHYL 5 HT; 2-METHYL-5-HT; CENTRAL STIMULANT AGENT; DRUG DERIVATIVE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; GROOMING; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SNIFFING; VENTRAL TEGMENTUM; WAKEFULNESS; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; ONDANSETRON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN AGENTS; VENTRAL TEGMENTAL AREA;

EID: 0029659044     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00028-3     Document Type: Article

References (57)

1. Azmitia, E.C., 1978, The serotonin-producing neurons of the midbrain medial and dorsal raphe nuclei, in: Handbook of Psychopharmacology, Vol. 9, Chemical Pathways in the Brain, ed. L.L. Iversen, S.D. Iversen and S.H. Snyder (Plenum Press, New York) p. 233.
2. 3H]-(S)-zacopride in the forebrain of the rat, Neuropharmacology 29, 1037.
3. Beart, P.M. and A.L. Gundlach, 1980, 3,4-Dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms, Br. J. Pharmacol. 69, 241.
4. Beart, P.M. and D. McDonald, 1982, 5-Hydroxytryptamine and 5-hydroxytryptaminergic-dopaminergic interactions in the ventral tegmental area of rat brain, J. Pharm. Pharmacol. 34, 591.
5. Beninger, R.J., 1983, The role of dopamine in locomotor activity and learning, Brain Res. Rev. 6, 173.
6. Bradley, P.B., G. Engel, W. Feniuk, J.R. Fozard, P.P.A. Humphrey, D.N. Middlemiss, E.J. Mylecharane, B.P. Richardson and P.R. Saxena, 1986, Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine, Neuropharmacology 25, 563.
7. 3 antagonist on drug-induced stimulation of dopamine release, Eur. J. Pharmacol. 164, 515.
8. 3 receptor antagonists block morphine- and nicotine-but not amphetamine-induced reward, Psychopharmacology 97, 175.
9. Carter, C.J. and C.J. Pycock, 1978, Differential effects of central serotonin manipulation on hyperactive and stereotyped behaviour, Life Sci. 23, 953.
10. 3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens, Brain Res. 543, 354.
11. Costall, B., R.J. Naylor and J.L. Neumeyer, 1975, Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas, Eur. J. Pharmacol. 31, 1.
12. Costall, B., S.-C.G. Hui and R.J. Naylor, 1979, The importance of serotonergic mechanisms for the induction of hyperactivity by amphetamine and its antagonism by intra-accumbens (3,4-dihydroxyphenylamino)-2-imidazoline (DPI), Neuropharmacology 18, 605.
13. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain, Br. J. Pharmacol. 92, 881.
14. 3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat, NeuroReport 1, 77.
15. 3 antagonist, ondansetron, in schizophrenia: results from uncontrolled trials, in: Novel Antipsychotic Drugs, ed. H.Y. Meltzer (Raven Press, New York) p. 225.
16. Evenden, J.L. and C.N. Ryan, 1988, Behavioral responses to psychomotor stimulant drugs: localization in the central nervous system, Pharmacol. Ther. 36, 151.
17. 3 receptors, in: Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications, eds. P.R. Saxena, D.I. Wallis, W. Wouters and P. Bevan (Kluwer, Dordrecht) p. 101.
18. 3H]LY278584, Brain Res. 553, 149.
19. 3-receptor-mediated modulation of mesolimbic locomotor activity in rats, Clin. Exp. Pharmacol. Physiol. Suppl. 18, 20.
20. 3 receptors in the ventral tegmental area, Clin. Exp. Pharmacol. Physiol. Suppl. 21, 23.
21. Guan, X.-M. and W.J. McBride, 1989, Serotonin microinfusion into the ventral tegmental area increses accumbens dopamine release, Brain Res. Bull. 23, 541.
22. 3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain, Eur. J. Pharmacol. 138, 303.
23. 3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat, Br. J. Pharmacol. 99, 227.
24. Hervé, D., V.M. Pickel, T.H. Joh and A. Beaudet, 1987, Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435, 71.
25. Hoyer, D., D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena and P.P.A. Humphrey, 1994, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin), Pharmacol. Rev. 46, 157.
26. 3 receptors control dopamine release in the nucleus accumbens of freely moving rats, Neurosci. Lett. 101, 214.
27. Jackson, D.M., N.-E. Andén and A. Dahlström, 1975, A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain, Psychopharmacologia (Berlin) 45, 139.
28. 3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric study, Brain Res. 513, 156.
29. 3 receptors, Soc. Neurosci. Abstr. 16, 1299.
30. Jones, D.L., G.J. Mogenson and M. Wu, 1981, Injections of dopaminergic, cholinergic, serotoninergic and gabaergic drugs into the nucleus accumbens: effects on locomotor activity in the rat, Neuropharmacology 20, 29.
31. Kennett, G.A. and T.P. Blackburn, 1991, Inhibition of agonist-induced dopamine release in the rat nucleus accumbens by BRL 46470, an in vivo dialysis study, Abstracts, 5-Hydroxytryptamine-CNS Receptors and Brain Function, Birmingham, UK, p. 103.
32. 3 receptors in rat brain using radioligand binding, Nature 330, 746.
33. 3 Receptors, ed. M. Hamon (Academic Press, London) p. 157.
34. Layer, R.T., N.J. Uretsky and L.J. Wallace, 1992, Effect of serotonergic agonists in the nucleus accumbens on d-amphetamine-stimulated locomotion, Life Sci. 50, 813.
35. Makanjuola, R.O.A., R.C. Dow and G.W. Ashcroft, 1980, Behavioural responses to stereotactically controlled injections of monoamine neurotransmitters into the accumbens and caudate-putamen nuclei, Psychopharmacology 71, 227.
36. McBain, S.L., M. Dineen, M. Weller, S. Taylor, P. Cooksey, P. Williams and T. Corn, 1992, Ondansetron: a double blind placebo controlled study in acute schizophrenia, Schizophren. Res. 6, 112.
37. Meltzer, H.Y., 1991, Studies of ondansetron in schizophrenia, in: Biological Psychiatry, Vol. 2, Proceedings of 5th World Congress of Biological Psychiatry, ed. G. Racagni, N. Brunello and T. Fukuda (Elsevier, Amsterdam) p. 891.
38. 3 receptor antagonists LY 277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells, Eur. J. Pharmacol. 209, 143.
39. 3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons, Eur. J. Pharmacol. 209, 151.
40. Minabe, Y., C.R. Ashby, Jr. and R.Y. Wang, 1992, Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on midbrain dopamine neurons, Eur. Neuropsychopharmacol. 2, 127.
41. Newcomer, J.W., W.O. Faustman, R.B. Zipursky and J.G. Csernansky, 1992, Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial, Arch. Gen. Psychiat. 49, 751.
42. Parsons, L.H. and J.B. Justice, Jr., 1993, Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis, Brain Res. 606, 195.
43. Paxinos, G. and C. Watson, 1986, The Rat Brain in Stereotaxic Coordinates, 2nd edn. (Academic Press, Sydney).
44. 3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat, Eur. J. Pharmacol. 230, 63.
45. 3H]quipazine in rodent brain, Eur. J. Pharmacol. 187, 75.
46. Pijnenburg, A.J.J., W.M.M. Honig and J.M. Van Rossum, 1975, Effects of antagonists upon locomotor stimulation induced by injection of dopamine and noradrenaline into the nucleus accumbens of nialamide-pretreated rats, Psychopharmacologia (Berlin) 41, 175.
47. 3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area, Eur. J. Pharmacol. 214, 13.
48. 3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons, Eur. J. Pharmacol. 205, 113.
49. Silverstone, P.H., B. Johnson and P.J. Cowen, 1992, Does ondansetron attenuate amphetamine-induced behaviour in human volunteers?, Psychopharmacology 107, 140.
50. 3 receptor antagonist, on A9 and A10 dopamine neurons, Eur. J. Pharmacol. 163, 115.
51. 3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol. Sci. 10, 127.
52. 3 Receptors, ed. M. Hamon (Academic Press, London) p. 189.
53. 3 receptors, Eur. J. Pharmacol. 213, 163.
54. 3 receptor agonist 2-methyl-5HT on the neuronal activity of A10 DA cells, Soc. Neurosci. Abstr. 16, 1299.
55. White, A., T.H. Corn, C. Feetham and C. Faulconbridge, 1991, Ondansetron in treatment of schizophrenia, Lancet 337, 1173.
56. Yoshimoto, K., W.J. McBride, L. Lumeng and T.K. Li, 1992, Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens, Alcohol 9, 17.
57. Zoldan, J., G. Friedberg, H. Goldberg-Stern and E. Melamed, 1993, Ondansetron for hallucinosis in advanced Parkinson's disease, Lancet 341, 562.